The Federal Trade Commission is opposing Illumina’s proposed $7.1 billion Grail acquisition, arguing that it will reduce competition for multi-cancer early detection tests. Illumina disagrees with the regulator’s position and will oppose the FTC’s challenge.| MedCity News
The lack of access to quality healthcare is often cited as the reason for maternal health disparities. But these issues go beyond access, according to Bayo Curry-Winchell, MD, founder of Beyond Clinical Walls and urgent care medical director at St. Mary’s Health Network.| MedCity News
We can’t wait for others to find a solution to high drug prices. It’s clear what should happen in a functioning drug pricing market federally and in California, but it is not happening today.| MedCity News
presented by | MedCity News
The White House might soon finalize a rule that will either save or cost patients billions of dollars in prescription drug costs. The rule concerns “copay accumulators,” which are programs health plans use to prevent copay assistance from counting toward patients’ deductibles or out-of-pocket maximums.| MedCity News
